uniQure announced their gene therapy AMT-060, received PRIME designation from the European Medicines Agency.
uniQure (NASDAQ:QURE) announced their gene therapy AMT-060, received PRIME designation from the European Medicines Agency, thanks to the results shown in the Phase 1/2 studies treating patients with severe hemophilia B.
As quoted in the press release:
“We are very pleased to have AMT-060 for hemophilia B accepted into the PRIME program,” stated Matthew Kapusta, chief executive officer of uniQure. “Similar to the Breakthrough Therapy designation that AMT-060 received from the U.S. Food and Drug Administration earlier this year, we look forward to this enhanced collaboration with the EMA to advance the clinical development of this potentially transformative therapy for hemophilia B patients.”